|
Nektar "verkauft" 2 Royalties für 150 Mio. $
endpts.com/...50m-in-cash-redoubling-focus-on-i-o-candidates/
www.healthcareroyalty.com/...antik-royalties-for-150-million/
Zahlen für Q1/21
"we remain on track to report the first data for our PROPEL study evaluating bempegaldesleukin plus pembrolizumab in patients with metastatic non-small cell lung cancer in the second half of 2021."
"For our second cytokine program in oncology, NKTR-255, our initial efforts include two Phase 1 clinical studies in combination with ADCC antibodies, one in hematological malignancies and one in solid tumors, and we look forward to sharing data from these studies in Q4 of this year,"
ir.nektar.com/news-releases/...quarter-2021-financial-results
Wer mit dem Gedanken spielt bei NKTR einzusteigen, für den könnten die aktuellen Kurse eine günstige Gelegenheit sein um eine erste Position aufzubauen.
Zahlen für Q2/21
"For bempegaldesleukin plus nivolumab, the first three of our five registrational studies in melanoma, renal cell carcinoma and bladder cancer remain on track for top line data in the first half of 2022. We are also evaluating the combination of bempegaldesleukin plus pembrolizumab and look forward to presenting data from the PROPEL study in patients with metastatic non-small cell lung cancer in the second half of 2021."
ir.nektar.com/news-releases/...-second-quarter-2021-financial
seekingalpha.com/news/...on-schedule-for-later-this-year-2022
2 Katalysatoren in den nächsten Quartalen
www.evaluate.com/vantage/articles/events/...ten-its-valuation
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
2 | 189 | Nektar Therap. - PEGylierung von Wirkstoffen = $$$ | Biotech4u | gdchs | 04.04.24 19:25 |